WOCKPHARMA

Wockhardt Share Price

₹1,316.55 -68.6 (-4.95%)

22 Feb, 2025 21:49

SIP TrendupStart SIP in WOCKPHARMA

Start SIP

Performance

  • Low
  • ₹1,316
  • High
  • ₹1,405
  • 52 Week Low
  • ₹490
  • 52 Week High
  • ₹1,680
  • Open Price₹1,392
  • Previous Close₹1,385
  • Volume346,082

Investment Returns

  • Over 1 Month -1.72%
  • Over 3 Month + 12.08%
  • Over 6 Month + 34.02%
  • Over 1 Year + 133.89%
SIP Lightning

Smart Investing Starts Here Start SIP with Wockhardt for Steady Growth!

Invest Now

Wockhardt Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -112
  • PEG Ratio
  • -1.8
  • Market Cap Cr
  • 21,392
  • P/B Ratio
  • 6.3
  • Average True Range
  • 85.2
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 7.7
  • RSI
  • 41.23
  • MFI
  • 42.83

Wockhardt Financials

Wockhardt Technicals

EMA & SMA

Current Price
₹1,316.55
-68.6 (-4.95%)
pointer
  • stock-down_img
  • Bearish Moving Average 11
  • stock-up_img
  • Bullish Moving Average 5
  • 20 Day
  • ₹1,427.10
  • 50 Day
  • ₹1,406.00
  • 100 Day
  • ₹1,309.46
  • 200 Day
  • ₹1,112.92

Resistance and Support

1345.8 Pivot Speed
  • R3 1,464.75
  • R2 1,434.85
  • R1 1,375.70
  • S1 1,286.65
  • S2 1,256.75
  • S3 1,197.60

What's your outlook on Wockhardt?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Wockhardt Ltd. is a global pharmaceutical and biotechnology company specializing in the development, manufacturing, and marketing of medicines, vaccines, and biosimilars. It focuses on key therapeutic areas including anti-infectives, cardiology, and diabetes care.

Wockhardt has an operating revenue of Rs. 2,969.00 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of -15% needs improvement, ROE of -13% is poor and needs improvement. The company has a reasonable debt to equity of 27%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 30% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 52 which is a POOR score indicating inconsistency in earnings, a RS Rating of 94 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 47 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Wockhardt Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-07 Quarterly Results
2024-11-13 Quarterly Results
2024-08-09 Quarterly Results
2024-05-28 Audited Results
2024-03-26 Others Inter alia, to consider and determine the issue price of Equity Shares to be issued pursuant to the Issue, including any discount, not more than 5%, on the floor price. issue of equity shares of Rs. 5/- each in the ratio of 3:10 @ premium of Rs. 220/-.

Wockhardt F&O

Wockhardt Shareholding Pattern

49.09%
7.13%
0.47%
6.54%
0%
27.49%
9.28%

About Wockhardt

  • NSE Symbol
  • WOCKPHARMA
  • BSE Symbol
  • 532300
  • Managing Director
  • Dr. Murtaza Khorakiwala
  • ISIN
  • INE049B01025

Similar Stocks to Wockhardt

Wockhardt FAQs

Wockhardt share price is ₹1,316 As on 22 February, 2025 | 21:35

The Market Cap of Wockhardt is ₹21392 Cr As on 22 February, 2025 | 21:35

The P/E ratio of Wockhardt is -112 As on 22 February, 2025 | 21:35

The PB ratio of Wockhardt is 6.3 As on 22 February, 2025 | 21:35

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23